Member Info for inanaco

being a shareholder guaranteed you a buy, why give that advantage to everyone, remember only Shareholders took the SP down ..... by selling, and any one selling below 12p needed help ... when the market was happy to oversubscribe

i just paid 12.44 on a �1k

TF ...... I gave a very reasoned response .. and left it with "Best of luck ... I wait your "risk analysis of the Science"" with interest He is Tosh ... exactly the same style, hence i knew he would not reply on the science

IFNγ is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops. Ifyn release has already been proven in patients ...... SCIB1 Ifyn release ... from CD4 t cells slewed to TH1 ... induce Ifyn release which is Why Moditope is a CD4 Th1 vaccine .. .. adjuvants induce this Th1 slew .. ISA Pharma plus Moditope .. .......

so you have to argue against this Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis remains poor. Therefore, the development of novel therapeutic strategies is urgently needed, and immunotherapy utilizing anti-programmed death 1/-programmed death ligand-1 mAb is an attractive approach. However, as there is limited information on how programmed death ligand-1 is upregulated on tumor cells within the tumor microenvironment, we examined the mechanism of programmed death ligand-1 regulation with a particular focus on interferon gamma in an in vitro setting and in clinical samples. Our in vitro findings showed that interferon gamma upregulated programmed death ligand-1 expression on solid tumor cells through the JAK-signal transducer and activator of transcription pathway, and impaired the cytotoxicity of tumor antigen-specific CTL against tumor cells. Following treatment of cells with anti-programmed death ligand-1 mAb after interferon gamma-pre-treatment, the reduced anti-tumor CTL activity by interferon gamma reached a higher level than the non-treatment control targets. In contrast, programmed death ligand-1 expression on tumor cells also significantly correlated with epithelial-mesenchymal transition phenotype in a panel of solid tumor cells. In clinical gastric cancer samples, tumor membrane programmed death ligand-1 expression significantly positively correlated with the presence of CD8-positive T cells in the stroma and interferon gamma expression in the tumor. The results suggest that gastric cancer patients with high CD8-positive T-cell infiltration may be more responsive to anti-programmed death 1/-programmed death ligand-1 mAb therapy. KEYWORDS: https://www.ncbi.nlm.nih.gov/pubmed/29034543 """""TILs from both SCIB1 and SCIB1+PD-1 vaccinated mice show enhanced IFNɣ release """"" https://en.wikipedia.org/wiki/Interferon_gamma https://www.scancell.co.uk/file-manager/scientific-papers/pivac-scib1-plus-checkpoint-inhibition.pdf Best of luck ... I wait your "risk analysis of the Science"" with interest

fair enough but you did not point that out ... and you post applied a blanket response to all his post ...which i have included. below On the contrary sir. Im sorry to say there has been the numerous claims made on this very BB that there is no risk and that the trials WILL be successful. I will leave it at that. The main thing is that there are people out there today who will have to continue to endure pain and hardship, because of these failures, which is a real shame, but as with most things, the fact that the world has the likes of LD working to eradicate these horrible diseases, is a beacon in the dark. She is the heroine here, and i salute her.

the risk is mitigated by the fact that multiple trials have been run now, showing synergy with PD1 using combo trials with vaccine type products ... The fact that immunobody is so successful inducing the correct "type" of T cell, indicates that a successful trial is very much in the offing, and i would not bet against failure but if your holding for a result without that under standing then you may consider it risky ... I really don't care, but if you can reason why the SCIENCE is risky then fair enough .... try it .. Always open for a discussion, but do your research otherwise you will find that discussion very difficult.and i leave no stone unturned

HotwingsToday 17:04Well on that we definitely all agree. all ... we ... who is All ?

so Boom I do not agree ..... so don't include "we" in your Post

"""""Im sorry to say there has been the numerous claims made on this very BB that there is no risk and that the trials WILL be successful. I will leave it at that.""""" The trial has been Successful ... SCIB1 PD1--- has been proved Successful If you understand the mechanism ... only an Idiot would back a Failure .. still "simple minds" made it to number 1 LOL

It helps that Scancell can pick the winners from the Uni Intake, and are in effect trained by Lindy from the start ..

As per RNS "The Placing and Subscription are not underwritten"

Thought that was on topic ..... Plenty of creative writers on these BB;s .. ... 7 patients become a Phase 3 asset in waiting expect them to be canned over time ....

No .... the market would smash Panmures ability in seconds. Price is at this level as buyers are in evidence

well C7 ... you have already had a big buy at 12p .. about �7.5m which was over subscribed we have another big buy coming at 12p ... a subscription ... from Pi .. whats interesting is why sell any below that ? LOL .. nothing stranger than folks playing on the stock market

No ... unless they had existing shares, so those that bought on the book build at 12p do not get another allocation of 1 for 20

That will give you an indicative indicator because SCIB1 outperforms Onconsecs products OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting SAN DIEGO, April 26, 2018 -- OncoSec Medical Incorporated (�OncoSec� or the �Company� (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, will present a trial-in-progress poster presentation from its global, multi-center, registration-directed open-label Phase 2b clinical trial, PISCES/KEYNOTE-695, assessing the OncoSec's investigational therapy, ImmunoPulse� IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation), and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy. The poster presentation will occur at the upcoming American Society of Clinical Oncology (ASCO) 2018 Annual Meeting to be held on June 1-5, 2018, in Chicago, IL.

failed

Failed ...

Failed ... LOL